Clinical Trial Search

Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…

Primary: Maximum Self-reported Pain Score on a Numeric Rating Scale — 7; 7 score on a scale

Primary: Likelihood of Accruing Participants: Feasibility of Enrollment — 27; 24 Participants

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg

Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day

Primary: Change in Mean Numeric Rating Scale at 5 Months From Baseline — -1.5 Units on a 0-10 scale

Primary: Pain Interference: Roland Morris Disability Questionnaire (RMDQ) — 8.028; 9.635; 9.034; 6.194 score on a scale

Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions

Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale

Primary: Change in Pain Severity Score — 6.44; 6.86; 8; 7.37 score on a scale — p=0.0303

Primary: Change in Anxiety: Depression Anxiety Stress Scale (DASS21). — 9.38; 10.1; 10.5; 9.85 units on a scale

Primary: Average Craving Level - Active vs. Control Messages — 4.736; 4.629 score on a scale

Primary: Change From Baseline in Cannabis Use at 10 Weeks — 268.8; 286.7; 490.3; 216.9 Ratio

Primary: fMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC). — .40; .33 Z score

Primary: Number of Participants With Biologically Verified 7-day Point Prevalence Tobacco Abstinence at the End of Treatment (Week 12) — 30; 40; 36; 42 Participants

Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…

Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33

Primary: Number of Participants Who Complete the Baseline Assessment — 18 Participants

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12 — -966.00; -532.81 ng/ml — p=.029

Primary: Numerical Pain Intensity — 6.03; 6.11; 6.24; 5.97 score on a scale — p=0.78

Primary: Maximum Tolerated Dose of Quetiapine — 197 milligrams

Primary: Number of Participants Achieving a Reduction in Pain Intensity of 30% or More — 18; 26; 35 participants — p=<.05

Primary: Cannabis Self-administration — 5.75; 9.2; 5.75; 7.5 puffs of cannabis chosen

Primary: Global Cognitive Ability (GCA) — -1.99; -0.82 Standard score (Z-score) — p=0.005

Primary: Phase 1 - Numerical Pain Rating Scale (NPRS) — 2.2; 2.6; 2.8; 1.4 units on a scale

Primary: Losartan Area Under the Curve (AUC) in Plasma — 164; 185; 289 h*ng/mL

Primary: Mean Difference in the Total Number of Errors From Paired Associates Learning (PAL) Module Averaged Over Weeks 1, 2, 3, and 4 — 5.6; 6.2; 5.9 score on a scale — p=0.215

Primary: 21 Days of Consecutive Abstinence as Measured by the Time-line Followback. — 18; 17 participants

Primary: Marijuana Self-administration - Progressive Ratio — 5.2; 4.5; 4.4 Progressive Ratios Completed

Primary: Change in Yale-Brown Obsessive Compulsive Scale — 24.0; 14.2; 2.5; 11.2 score on a scale